Synthesis and biological evaluation of some novel sulfamoylphenyl- pyridazinone as anti-inflammatory agents (Part-II)

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 27, Issue 1, 2012, Pages 92-96

  Bashir, Rafia ^a   Yaseen, Shafiya ^a   Ovais, Syed ^a   Ahmad, Shamim ^a   Hamid, Hinna ^a   Alam, M S ^a   Samim, Mohammad ^a   Javed, Kalim ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Anti inflammatory; Benzenesulfonamide; Pyridazinone

Indexed keywords

6 (2',4' DIMETHYLPHENYL) 2 (4 SULFAMOYLPHENYL) 4,5 DIHYDROPYRIDAZIN 3(2H)ONE; 6 (3',4' DICHLOROPHENYL) 2 (4 SULFAMOYLPHENYL) 4,5 DIHYDROPYRIDAZIN 3(2H)ONE; 6 (3',4' DIMETHOXYPHENYL) 2 (4 SULFAMOYLPHENYL) 4,5 DIHYDROPYRIDAZIN 3(2H)ONE; 6 (4' BROMOPHENYL) 2 (4 SULFAMOYLPHENYL) 4,5 DIHYDROPYRIDAZIN 3(2H)ONE; 6 (4' PHENOXYPHENYL) 2 (4 SULFAMOYLPHENYL) 4,5 DIHYDROPYRIDAZIN 3(2H)ONE; 6 (4' PHENYLPHENYL) 2 (4 SULFAMOYLPHENYL) 4,5 DIHYDROPYRIDAZIN 3(2H)ONE; 6 (BETA NAPTHYL) 2 (4 SULFAMOYLPHENYL) 4,5 DIHYDROPYRIDAZIN 3(2H)ONE; ALCOHOL; ANTIINFLAMMATORY AGENT; BENZENESULFONAMIDE DERIVATIVE; CARRAGEENAN; CELECOXIB; PYRIDAZINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; EVALUATION; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; ULCEROGENESIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARRAGEENAN; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EDEMA; FEMALE; MALE; MOLECULAR STRUCTURE; PYRIDAZINES; RATS; RATS, WISTAR;

RATTUS;

EID: 84855393393     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2011.577036     Document Type: Article

References (31)

1. Siddiqui AA, Kushnoor A, and Wani SM. Synthesis and hypotensive activity of some 6-(substituted aryl)-4-methyl-2,3-dihydropyridazin-3-ones. Indian J Chem-B 2004;43B:1574-1579
2. Banerjee PS, Sharma PK, and Nema RK. Synthesis and anticonvulsant activity of pyridazinone derivatives. Int J Chem Tech Research 2009;1:522-525
3. Tanaka H, Kirihara S, Yasumatsu H, Yakushiji T, and Nakao T. Synthesis and evaluation of novel 2-aryl-2,5,6,7-tetrahydro-3Hthieno[ 2',3':6,7] cyclohepta[1,2-c]pyridazin-3-ones and 2-aryl-5,6-dihydrothieno[2,3-h]cinnolin- 3(2H)-ones as anxiolytics. Eur J Med Chem 1997;32:607-615. (Pubitemid 27321184)
4. Pinna GA, Curzu MM, Murineddu G, Chelucci G, Cignarella G, Menta E et al. Preparation of thieno[3,2-h]cinnolinones as matrix metalloproteinase inhibitors. Arch Pharm (Weinheim) 2000;333:37-47. (Pubitemid 30211867)
5. Pau A, Asproni B, Boatto G, Grella GE, De Caprariis P, Costantino L et al. Synthesis and aldose reductase inhibitory activities of novel thienocinnolinone derivatives. Eur J Pharm Sci 2004;21:545-552. (Pubitemid 38283929)
6. Kwon SK, Moon A. Synthesis of 3-alkylthio-6-allylthiopyridazine derivatives and their antihepatocarcinoma activity. Arch Pharm Res 2005;28:391-394. (Pubitemid 43073645)
7. Sönmez M, Berber I, Akbas E. Synthesis, antibacterial and antifungal activity of some new pyridazinone metal complexes. Eur J Med Chem 2006;41:101-105. (Pubitemid 43276064)
8. Harris RR, Black L, Surapaneni S, Kolasa T, Majest S, Namovic MT et al. ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4- methanesulfonyl-phenyl)-2Hpyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitor. J Pharmacol Exp Ther 2004;311:904-912. (Pubitemid 39612694)
9. Estevez I, Ravina E, Sotelo E. Synthesis of 6-aryl-5-amino-3(2H)- pyridazinones as potential platelet aggregation inhibitors. J Heterocyclic Chem 1998;35:1421-1428. (Pubitemid 29048501)
10. Haider N, Hartmann RW, Steinwender A. Synthesis of 2-[2-(1-imidazolyl) ethyl]-4-phenylcycloalka [ g[ phthalazin-1(2H)-ones as thromboxane A 2 synthase inhibitors, Arch Pharm Pharm Med Chem 1999;332:408-409.
11. Amgad G, Habeeb PN, Parveen R, Edward EK. Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: Replacement of sulphonamide and methylsulfonyl pharmacophores by an azido bioisosters. J Med Chem 2001;44:3039-3042.
12. Sotelo E, Fraiz N, Yáñez M, Laguna R, Cano E, Brea J et al. Pyridazines. Part 28: 5-alkylidene-6-phenyl-3(2H)-pyridazinones, a new family of platelet aggregation inhibitors. Bioorg Med Chem Lett 2002;12:1575-1577. (Pubitemid 34569246)
13. Coelho A, Sotelo E, Fraiz N, Yáñez M, Laguna R, Cano E et al. Pyridazines. Part 36: Synthesis and antiplatelet activity of 5-substituted-6-phenyl-3(2H)-pyridazinones. Bioorg Med Chem Lett 2004;14:321-324. (Pubitemid 38045114)
14. Van der Mey M, Boss H, Couwenberg D, Hatzelmann A, Sterk GJ, Goubitz K et al. Novel selective phosphodiesterase (PDE4) inhibitors. 4. Resolution, absolute configuration, and PDE4 inhibitory activity of cis-tetra-and cis-hexahydrophthalazinones. J Med Chem 2002;45:2526-2533. (Pubitemid 34595222)
15. Van der Mey M, Bommelé KM, Boss H, Hatzelmann A, Van Slingerland M, Sterk GJ et al. Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents. J Med Chem 2003;46:2008-2016. (Pubitemid 36532243)
16. Gilchrest BA, Eller MS. Cancer therapeutics: smart and smarter. Drugs of the Future 2009;34:205-216.
17. Pau A, Murineddu G, Asproni B, Murruzzu C, Grella GE, Pinna GA et al. Synthesis and cytotoxicity of novel hexahydrothienocycloheptapyridazinone derivatives. Molecules 2009;14:3494-3508.
18. Drew J. Drug discovery: A historical perspective. Science 2000;287:1960-1964.
19. Supuran CT and Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. Exp Opin Ther Patents 2000;10:575-600. (Pubitemid 30251754)
20. Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors. Curr Med Chem Immunol Endoc Metab Agents 2001;1:61-97.
21. Maren TH. Relations between structure and biological activity of sulfonamides. Annu Rev Pharmacol Toxicol 1976;16:309-327.
22. Boyd AE 3rd. Sulfonylurea receptors, ion channels, and fruit flies. Diabetes 1988;37:847-850.
23. Thornber CW. Isosterism and molecular modification in drug design. Chem Soc Rev 1979;8:563-580.
24. Ogden RC, Flexner CW. (2001). Protease Inhibitors in AIDS Therapy. New York, Basel: Marcel Dekker.
25. Supuran C, Scozzafava A, Mastrolorenzo A. Bacterial proteases: current therapeutic use and future prospects for the development of new antibiotics. Expert Opin Ther Patents 2001;11:221-259. (Pubitemid 32117923)
26. Scozzafava A, Supuran CT. Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. J Med Chem 2000;43:3677-3687.
27. Casini A, Scozzafava A, Mastrolorenzo A, Supuran LT. Sulfonamides and sulfonylated derivatives as anticancer agents. Curr Cancer Drug Targets 2002;2:55-75. (Pubitemid 34627379)
28. Khanna IK, Weier RM, Yu Y, Collins PW, Miyashiro JM, Koboldt CM et al. 1,2-Diarylpyrroles as potent and selective inhibitors of cyclooxygenase-2. J Med Chem 1997;40:1619-1633. (Pubitemid 27231465)
29. Bashir R. (2010). Thesis, Synthesis of novel heterocyclic compounds of pharmaceutical interest. New Delhi, India: Jamia Hamdard.
30. Winter CA, Risley EA, Nuss GW. Carrageenin-induced edema in hind paw of the rat as an assay for antiiflammatory drugs. Proc Soc Exp Biol Med 1962;111:544-547.
31. Rathish IG, Javed K, Ahmad S, Bano S, Alam MS, Pillai KK et al. Synthesis and antiinflammatory activity of some new 1,3,5-trisubstituted pyrazolines bearing benzene sulfonamide. Bioorg Med Chem Lett 2009;19:255-258.